Envelope Determinants of Equine Lentiviral Vaccine Protection

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Craigo, Jodi K ^a,b   Ezzelarab, Corin ^a   Cook, Sheila J ^c   Chong, Liu ^c   Horohov, David ^c   Issel, Charles J ^c   Montelaro, Ronald C ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUINE LENTIVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGENIC VARIATION; ARTICLE; EQUINE INFECTIOUS ANEMIA; EV0 STRAIN; EV13 STRAIN; GENE MAPPING; GENE SEQUENCE; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; NONHUMAN; PATHOGENICITY; SEQUENCE HOMOLOGY; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; CELL LINE; EQUINE INFECTIOUS ANEMIA; GENE ORDER; GENOME, VIRAL; HORSES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFECTIOUS ANEMIA VIRUS, EQUINE; PROVIRUSES; RECOMBINATION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL VACCINES; VIRULENCE;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 84878983485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066093     Document Type: Article

References (75)

1. Mims CA (1987) The Pathogenesis of Infectious Diseases. SanDiego: Academic. 303-321.
2. Melink JA, Plotkin SA, Mortimer EA, Saunders WB (1994) Vaccines. SanDiego: Academic. 155-204.
3. Hambleton S, (2008) Prevention of varicella and zoster by live attenuated VZV vaccine. Front Biosci 13: 2696-2704.
4. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820-1825.
5. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5: 194-203.
6. Berkhout B, Verhoef K, Van Wamel JL, Back NK, (1999) Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 73: 1138-1145.
7. Ruprecht RM, (1999) Live attenuated AIDS viruses as vaccines: promise or peril? Immunol Rev 170: 135-149.
8. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, Mcclure HM, et al. (2003) Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157-166.
9. Whitney JB, Ruprecht RM, (2004) Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17: 17-26.
10. Das AT, Baldwin CE, Vink M, Berkhout B, (2005) Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry. J Virol 79: 3855-3858.
11. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al. (2008) Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205: 2537-2550.
12. Kumar A, Liu Z, Sheffer D, Smith M, Singh DK, et al. (2008) Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration. Virology 371: 238-245.
13. Montelaro RC, Ball JM, Rushlow K (1993) Equine retroviruses. In: Levy JA, editor. The Retroviridae. New York, N.Y.: Plenum Press. 257-360.
14. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, et al. (2000) Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74: 3112-3121.
15. Hammond SA, Li F, Mckeon BM Sr, Cook SJ, Issel CJ, et al. (2000) Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74: 5968-5981.
16. Craigo J, Montelaro R (2008) Equine Infectious Anemia Virus (Retroviridae). Encyclopedia of Virology. Third ed. Oxford: Elsevier. 167-174.
17. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T, (1976) Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs. Natl Inst Anim Health Q (Tokyo) 16: 8-15.
18. Craigo JK, Leroux C, Howe L, Steckbeck JD, Cook SJ, et al. (2002) Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol 83: 1353-1359.
19. Craigo JK, Sturgeon TJ, Cook SJ, Issel CJ, Leroux C, et al. (2006) Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 344: 340-353.
20. Issel CJ, Horohov DW, Lea DF, Adams WV Jr, Hagius SD, et al. (1992) Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66: 3398-3408.
21. Wang SZ, Rushlow KE, Issel CJ, Cook RF, Cook SJ, et al. (1994) Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199: 247-251.
22. Raabe ML, Issel CJ, Cook SJ, Cook RF, Woodson B, et al. (1998) Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245: 151-162.
23. Hammond SA, Cook SJ, Falo LD Jr, Issel CJ, Montelaro RC, (1999) A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 254: 37-49.
24. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, et al. (2003) A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77: 7244-7253.
25. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, et al. (2005) Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 79: 2666-2677.
26. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, et al. (2007) Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 25: 834-845.
27. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, et al. (2007) Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 104: 15105-15110.
28. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC, (2010) Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 28: 8095-8104.
29. Montelaro RC, Wigzell H (1995) AIDS 1995. Vaccines and immunology: overview. AIDS 9 Suppl A: S111-112.
30. Mills J, Desrosiers R, Rud E, Almond N, (2000) Live attenuated HIV vaccines: a proposal for further research and development. AIDS Res Hum Retroviruses 16: 1453-1461.
31. Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK, (2002) FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol 90: 113-132.
32. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19-23.
33. Tagmyer TL, Craigo JK, Cook SJ, Issel CJ, Montelaro RC, (2007) Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 88: 1324-1336.
34. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, et al. (2008) Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 82: 4052-4063.
35. Payne SL, Fang FD, Liu CP, Dhruva BR, Rwambo P, et al. (1987) Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 161: 321-331.
36. Hussain KA, Issel CJ, Schnorr KL, Rwambo PM, West M, et al. (1988) Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90. Arch Virol 98: 213-224.
37. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC, (1990) In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch Virol 111: 275-280.
38. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, et al. (1990) Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection. Arch Virol 111: 199-212.
39. Lichtenstein DL, Rushlow KE, Cook RF, Raabe ML, Swardson CJ, et al. (1995) Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J Virol 69: 2881-2888.
40. Lichtenstein DL, Issel CJ, Montelaro RC, (1996) Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70: 3346-3354.
41. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC, (1997) Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71: 3840-3852.
42. Leroux C, Issel CJ, Montelaro RC, (1997) Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71: 9627-9639.
43. Li F, Leroux C, Craigo JK, Cook SJ, Issel CJ, et al. (2000) The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J Virol 74: 573-579.
44. Leroux C, Craigo JK, Issel CJ, Montelaro RC, (2001) Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75: 4570-4583.
45. Howe L, Leroux C, Issel CJ, Montelaro RC, (2002) Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 76: 10588-10597.
46. Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, et al. (2009) An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family. Retrovirology 6: 95.
47. Coggins L, Norcross NL, (1970) Immunodiffusion reaction in equine infectious anemia. Cornell Vet 60: 330-335.
48. Shen RX, Wang Z (1985) Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine. EIAV: A National Review of Policies, Programs, and Future Objectives. Amarillo, Texas: American Quater Horse Association.
49. Johnson RP, Desrosiers RC, (1998) Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 10: 436-443.
50. Johnson RP, (1999) Live attenuated AIDS vaccines: hazards and hopes. Nat Med 5: 154-155.
51. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, et al. (1999) Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73: 4952-4961.
52. Almond N, Stott J, (1999) Live attenuated SIV-a model of a vaccine for AIDS. Immunol Lett 66: 167-170.
53. Bogers WM, Cheng-Mayer C, Montelaro RC, (2000) Developments in preclinical AIDS vaccine efficacy models. AIDS 14Suppl 3: S141-151.
54. Blower SM, Koelle K, Kirschner DE, Mills J, (2001) Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci U S A 98: 3618-3623.
55. Kumar A, Mukherjee S, Shen J, Buch S, Li Z, et al. (2002) Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 301: 189-205.
56. Abel K, Compton L, Rourke T, Montefiori D, Lu D, et al. (2003) Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J of Virol 77: 3099-3118.
57. Amara RR, Patel K, Niedziela G, Nigam P, Sharma S, et al. (2005) A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J Virol 79: 15356-15367.
58. Busch M, Abel K, Li J, Piatak M Jr, Lifson JD, et al. (2005) Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge. Vaccine 23: 4036-4047.
59. Zheng YH, Nakaya T, Sentsui H, Kameoka M, Kishi M, et al. (1997) Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse. J Gen Virol 78 (Pt 4): 807-820.
60. Zheng YH, Sentsui H, Nakaya T, Kono Y, Ikuta K, (1997) In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain. J Virol 71: 5031-5039.
61. Howe L, Craigo JK, Issel CJ, Montelaro RC, (2005) Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain. J Gen Virol 86: 139-149.
62. Sponseller BA, Sparks WO, Wannemuehler Y, Li Y, Antons AK, et al. (2007) Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease. Virology 363: 156-165.
63. Ball JM, Rushlow KE, Issel CJ, Montelaro RC, (1992) Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol 66: 732-742.
64. Papandreou MJ, Idziorek T, Miquelis R, Fenouillet E, (1996) Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions. FEBS Lett 379: 171-176.
65. Shental-Bechor D, Levy Y, (2008) Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci U S A 105: 8256-8261.
66. Haynes BF, Gilbert PB, Mcelrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
67. Mcmichael AJ, Haynes BF, (2012) Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 13: 423-427.
68. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441.
69. Li F, Puffer BA, Montelaro RC, (1998) The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 72: 8344-8348.
70. Grund CH, Lechman ER, Issel CJ, Montelaro RC, Rushlow KE, (1994) Lentivirus cross-reactive determinants present in the capsid protein of equine infectious anaemia virus. J Gen Virol 75 (Pt 3): 657-662.
71. Craigo JK, Ezzelarab C, Montelaro RC, (2012) Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods 185: 221-227.
72. Raabe MR, Issel CJ, Montelaro RC, (1998) Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus. J Virol Methods 71: 87-104.
73. Leroux C, Cadore JL, Montelaro RC, (2004) Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet Res 35: 485-512.
74. Cook RF, Cook SJ, Li FL, Montelaro RC, Issel CJ, (2002) Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV). J Virol Methods 105: 171-179.
75. Montelaro RC, Cole KS, Hammond SA, (1998) Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 14Suppl 3: S255-259.